Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. - Aix-Marseille Université Access content directly
Journal Articles Antiviral Therapy Year : 2019

Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.

Antoine Frangeul
  • Function : Author
Cécile Bussetta
  • Function : Author
Jérôme Deval
  • Function : Author

Abstract

In the treatment of HIV, the loose active site of the HIV-1 reverse transcriptase (RT) allows numerous nucleotide analogues to act as proviral DNA 'chain-terminators'. Acyclic nucleotide phosphonate analogues (ANPs) represent a particular class of nucleotide analogue that does not possess a ribose moiety. The structural basis for their substrate efficiency regarding viral DNA polymerases is poorly understood.
No file

Dates and versions

hal-02061712 , version 1 (08-03-2019)

Identifiers

  • HAL Id : hal-02061712 , version 1
  • PUBMED : 18389906

Cite

Antoine Frangeul, Cécile Bussetta, Jérôme Deval, Karine Barral, Karine Alvarez, et al.. Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.. Antiviral Therapy, 2019, 13 (1), pp.115-24. ⟨hal-02061712⟩
29 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More